A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies-Reference-Cited by-同舟云学术

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

Published:2022-03-06 Issue:2 Volume:3 Page:434-442
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

How Joan¹^ORCID,Ren Siyang²,Lombardi‐Story Jennifer³,Bergeron Meghan³,Foster Julia³,Amrein Phillip C.³,Brunner Andrew M.³,Fathi Amir T.³,Hock Hanno³,Khachatryan Anna⁴,Kikuchi Hiroto⁴,Ng Mei Rosa⁴,Moran Jenna³,Narayan Rupa³,Neuberg Donna²,Ramos Aura³,Som Tina³,Vartanian Meghan³,Chen Yi‐Bin³,Duda Dan G.⁴,Hobbs Gabriela S.³

Affiliation:

1. Division of Hematology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

2. Department of Data Sciences Dana‐Farber Cancer Institute Boston Massachusetts USA

3. Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

4. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.408

Reference32 articles.

1. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

2. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

3. Evidence of increased angiogenesis in patients with acute myeloid leukemia

4. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia

5. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia